Literature DB >> 2479031

Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

V Karacostas1, K Nagashima, M A Gonda, B Moss.   

Abstract

Infectious retrovirus particles consist of a core structure containing RNA and gag-pol polypeptides surrounded by a lipid membrane studded with env proteins. A recombinant vaccinia virus was designed to express the entire gag-pol precursor protein of the human immunodeficiency virus type 1. Synthesis and processing of gag proteins occurred in mammalian cells infected with this live recombinant virus, and reverse transcriptase was detected largely in the medium. Electron micrographs revealed immature retrovirus-like particles budding from the plasma membrane and extracellular particles with morphological characteristics of immature and mature human immunodeficiency virus. The latter contained functional reverse transcriptase as well as processed p24 and p17 gag polypeptides. Thus, assembly and maturation of human immunodeficiency virus-like particles can occur in the absence of either infectious RNA molecules or env proteins. The production of noninfectious virus-like particles by expression vectors should be useful for biochemical studies and could provide a safe source of material for the development of vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479031      PMCID: PMC298411          DOI: 10.1073/pnas.86.22.8964

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

4.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

5.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

6.  Deficiency of 60 to 70S RNA in murine leukemia virus particles assembled in cells treated with actinomycin D.

Authors:  J G Levin; P M Grimley; J M Ramseur; I K Berezesky
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

Review 7.  The genetics of murine leukemia viruses.

Authors:  S P Goff
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

8.  Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus.

Authors:  M A Gonda; F Wong-Staal; R C Gallo; J E Clements; O Narayan; R V Gilden
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

9.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

10.  Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24.

Authors:  F D Veronese; T D Copeland; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

View more
  103 in total

1.  Role of rubella virus glycoprotein domains in assembly of virus-like particles.

Authors:  M Garbutt; L M Law; H Chan; T C Hobman
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Role of RNA in facilitating Gag/Gag-Pol interaction.

Authors:  Ahmad Khorchid; Rabih Halwani; Mark A Wainberg; Lawrence Kleiman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1.

Authors:  Rabih Halwani; Ahmad Khorchid; Shan Cen; Lawrence Kleiman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Determination of influenza virus proteins required for genome replication.

Authors:  T S Huang; P Palese; M Krystal
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Nuclear RNA export and packaging functions of HIV-1 Rev revisited.

Authors:  Maik Blissenbach; Bastian Grewe; Bianca Hoffmann; Sabine Brandt; Klaus Uberla
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

6.  Defective retroviruses can disperse in the human genome by intracellular transposition.

Authors:  T Tchenio; T Heidmann
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

7.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

Review 10.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.